As CDK6 participates in cell cycle dysregulation in many solid tumors and lymphoma (6, 8), there is a potential benefit of CDK4/6 inhibitors for the treatment of these tumors (23); however, de novo or acquired treatment resistance has also been reported in several tumor models. Here, CDK6 is linked to neoplasm.